SLDB - Earnings call transcript Q1 2021

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by and welcome to the Solid Biosciences Update Call. At this time all participants are in a listen-only mode. [Operator Instructions] I would now like to hand the conference over to your speaker today, Mr. Tim Palmer, Corporate Communications Manager at Solid Biosciences. Sir, you may begin.

Tim Palmer

operator. you thank morning, Good

financial Before statements we that the forward to everyone and financial would statements, operations strategies and product started, this conference I development results, a company’s from in these during in forward-looking the about the trial. make progress, development statements like Co-Founder, future filed clinical pandemic call, uncertainty this of obligation business Chief discussed call. XX-K DMD the including clinical important and Actual results including including due process, those and remind to regulatory about number get guidance, risks regulatory Scientific Chief ongoing IGNITE we Dr. could and of looking me factors, Form call after Factors may filed Annual of on Clary, and Executive differ Operating and today’s of impact Morris, other the in our materially Ilan Carl of periodic duration and statements inherent extent recently any the update described With Officer; Officer. the Biosciences; no Acting Report Joel our other Chief undertake the date Schneider, President Cathryn Officer SEC. We reports on section Officer; our COVID-XX statements and Risk forward-looking Medical Solid with to Dr. most of Chief the Ganot, are our

over Ilan? I’d to For Ganot, turn call Ilan opening remarks, like the to

Ilan Ganot

what means XXXX continue Thank you muscular update our with to provide current an dystrophy. as corporate patients along corporate our The goals progress you, joining is progress Tim. call morning for today’s focus Good and thank Duchenne we on today. also our on and us activities

produced were update amended our IGNITE First, protocol. with clinical an DMD on dosed improved SGT-XXX using dosing patients in we quarter process manufacturing under in provide and IGNITE this Two DMD. an

dosed, and of Patient the X or has do are adverse serious on X to patient event Patient been well. dosed experienced or the to patients safely to SAE, its Cathryn towards moment, has reporting as values we review reported discharged, visits course. and SAE either are an have previously trade the normal. we Today, to additional Dr. taking a As to In normal follow-up evaluate been but this and trend steps continues since lab Clary XX-day returned will continue

nomination To at at months supportive of at preclinical we that in Cathryn’s believe review Schneider, Joel novel generation also fronts. XX SGT-XXX trends dosing enable of captured microdystrophin Ultragenyx. Today first encouraging this present progress a benefit Chief pleased establish knowledge novel will these study. data Morris Carl the long-term Meeting. is presented presenting of from next and program all we microdystrophin growing Carl is clinical Gene being next XX in collaboration the will recently the microdystrophin an patient experience, our Officer, the Society the from data update reported candidate vg/kg our gene data construct IGNITE that to be today ASGCT. provide dose dose. months expression Solid’s on from DMD the biomarker risk program which trial will our Operating Dr. Cell collected meaningful pipeline, dosed DMD Duchenne. Dr. includes to out patients and the Duchenne of of an a SGT-XXX on on clinical capsid cells. IGNITE conjunction with our with have our enhanced our positive with gene Data clinical Duchenne to for therapy our ongoing proprietary durable therapy functional show months. delivery SGT-XXX will American and dosing, In a XX on Therapy totality data development and potentially with to Following also to expression the to profile of be also I’m biopsy share, the providing our first three muscle will sustained for update Annual XEXX later with combine data for patients evidence are our The the

as of continue to call who turn we support program. therapies. the long-term the generate steps and clinical evidence to will As we additional the to pipeline update gene I’ll our while SGT-XXX now are Cathryn review of expanding our we briefly potential the SGT-XXX differentiated taking progress over

Cathryn Clary

Ilan. you, Thank

amended As enrollment we DMD resumed and subsequently patients protocol. in in IGNITE reported clinical our March, if two under we dosed

our generated with with days working DSMB period all a built-in of waiting or to Board closely dosing. minimum carefully As each review we’re between a Data Safety Monitoring data reminder, the XX

previously reported also uneventfully XEXX at vg/kg and do dosed dosed the to continue was the Patient We well. X

response, adverse described we serious brochure patient throughout patients, experienced data year. considered and additional is by drug which as we’ll unexpected. classified our do is As are event the all be we with the to we’re investigators monitor continuing event inflammatory collecting investigator be This this in sharing a the was X, and Patient considered to and an related. Today, not

and clinical are as of and outcome to this follow-up further the returned our with and working values the may also internally, moving it normal. SAE had understanding with strategy either XX-day of towards trend closely dosing this visit to of shared well data We impact continue forward. DSMB to the laboratory external how related the the As normal as patient’s both or to IGNITE experts FDA our

potential analyze us to us before enhance Duchenne. is to of the now continuing support turn long-term make waiting provide with to This data what, determine to IGNITE to had to biopsy event X which already allow we from will will changes days to to X, Carl? additional patient of might who DMD. dosing and the SGT-XXX we minimum any our Carl carefully benefit we review the of clinical if this While dose further patients a in priority. protocol data top I’ll to period complexity call always the X Patients XX built-in which X, Patients believe all between over requires safety, the patients the

Carl Morris

XX to long-term proprietary I’m X share at leads analysis binding nNOS months, X compelling taken SGT-XXX. our for baseline to from biopsy the dosing quadricep vg/kg excited Today, you, Thank microdystrophin up Oxide XX X months collected which and post that The left the post to to and right X, time and SGT-XXX the the of were day sustained expression provide were of was from containing construct acquired from while the of quadriceps, XEXX each of or dose respectively patients muscle. patient, dosing. The biopsies XX, Synthase last evidence data from neuronal muscle biopsies taken dose Patients at XX single a XX to sample the Cathryn. the Nitric the domain

but of at Over slides, you, I as in microdystrophin microdystrophin dystrophin as levels to expression remains with all I highlighting biopsies, demonstrate few will comparable a Western will the and the associated protein Blot through through data dose. protein observed three this the patients immunofluorescence that next biopsies beta-sarcoglycan, you from co-localization high function, then the walk results, well long-term share day-XX nNOS. the

all observed positive last the XX Patients overall patients in we positive trends that we time functional of biomarker look we’ll biopsies fibers baseline day longer-term Slide only morphological that microdystrophin at to clinical And through pathology from the in as shared are months. their biopsies. shared XX. analysis so points potentially positive March. microdystrophin the the the and shared data three for baseline the reporting X long-term active day these we in fibers Finally, proportion at day-XX X shows, destructive at seen time X muscle previously Collectively minimal data, the results that weren’t today, maintained in the since of in are demonstrate of point, biopsies is and muscle the up which immunofluorescence data XX mild deterioration samples, with some supportive

to X Western top X collected fibers shows months Specifically, at at On in XX X, panel the has to Patients positive and seemed to XX at XX% XX% X XX% bottom X Patient then months. positive X the showed in and dosing. fibers has positive fibers we data for have Patient Patient months, while XX% XX% post muscle Blot panel. XX Patients X Slide

side, of XX right in level XX but for shown Patient X months. of table microdystrophin dystrophin, X% be the seemed to out day months As below microdystrophin normal the quantitation XX.X% remains is of normal level patients level hand at to on it’s of to at the XX. still detectable XX.X% compared

see figure The X months and of three was the summarizes for normal mentioned there remains average Patient Patients XX at at a interestingly, X% XEXX of that shows dosing X%. the expression two found quantitation post Slide increase Western last Patient I months both expression clearly years X slide, can is X, up of Blot left of patients X apparent day For and the an microdystrophin while in but compared to on by upper levels post as IF Western detectable, assessed XX. the to of Blot, quantifiable microdystrophin level expression dose. microdystrophin you level had the below at for three both vg/kg XX.X% an X, on

to middle restoration immunofluorescence microdystrophin right to images column hand in additional the proteins shown these to yellow. of point. analysis left functional persistent, remain column a red, microdystrophin muscle levels in green, comparable are show observed in of muscle in while proteins On the biopsies, cell says, we’ve results fibers. appear the membrane dystrophin the and muscle time seen validated fibers from of merged with on the XX co-localized we XX-month the right analysis. measurement samples. out beta-sarcoglycan the and results The positive side, positive our co-localization associated stable, Switching in The day microdystrophin the shows column the They automated to shows the two

the nNOS nNOS see muscle durable microdystrophin dark demonstrate On at with at the the purple using of recruit cell looking microdystrophin and capacity of continued the The co-localize evidence to Again, red the observed indicated activity shows panel months. the provides cell muscle these demonstrates stain XX microdystrophin analysis localization proteins The protein. while can shows XX about activity muscle patient at of the localization additional of in sarcolemma. in staining to slide aligning proteins shown membrane muscle the XX, baseline XX and as functionality these months biopsies These membrane. nNOS muscle from we to left you associated right long-term a as our results the each microdystrophin show nNOS by both enzymatic membrane. our activity on staining expression activity next membrane, histological biopsies to construct. simple days and As dystrophin to Slide has membrane, which an two to the

long-term the time muscle of muscle limited and active two loss. see these variable mild dystrophic disease biopsy the progression in out to have showed to progression point, encouraging only changes and to slowing supporting of Although dystrophic is muscle baseline role between of years pathology degrees observed, pathology microdystrophin out

So, The biopsies muscle minimal of overall out demonstrate potentially the expression previously map. reported and new deterioration positive the increased provides encouraging long-term XX to potential are the to the reported data XX functional months. clinical as results as persistent and between from months recently efficacy since these and the heat for from the XX on and days IGNITE support DMD microdystrophin progression biomarker they trends baseline summarized

my today I’ll of data be talk at the X:XX be posted p.m. the noted complete. to Solid Ilan As ASGCT the once will full Conference, my presenting is presentation at call, the Biosciences start these website at

it preclinical turn update Joel over Now, for I’ll the to on pipeline. an

Joel Schneider

the a for look with Thanks data body to we It’s Duchenne to very SGT-XXX to generating supporting provide patients program. of forward more benefit and potential encouraging, for this evidence Carl. growing is

remains in DMD, SGT-XXX patients advancing IGNITE additional dose we our while As priority.

that tropism our and of We AAVX with developed transfer at and Dr. and with demonstrate Today by the by needs and to microdystrophin that developed been that and capsids. the have new actively therapy a Meeting we corresponds novel announcing have is in Duchenne novel internally liver Data rationally next ASGCT a Green preclinical we library distribution other our leverages to expertise with broad outcomes muscle program improve presented end, address program designed in that successfully gene muscle a biology. asset an innovative based vitro decreases increased of gene capsids SGT-XXX combines patients of called Jennifer with designed vivo disorders. library in with compared improved ways to Toward generation a various candidate is drive are in that musculoskeletal to Duchenne This with to in microdystrophin. SGT-XXX. evaluating and delivery AAVX containing potentially continue preclinical proprietary models. explore our muscles enhance we for novel patients capsid efficiency nNOS

in advances We we you exploring summarizes as conducting months. program And with the data candidate clinic with optimization study, data lead timeline capsid dose XX alongside are to for the to this potential a from forward additional SGT-XXX. response currently slide look sharing SLBXXX. This approximately AAVX

doses can to expression. you at increase are and distribution see by As novel all, led microdystrophin ultimately capsid

program provide internal additional progress SGT-XXX, as other leverage We will our pipeline and candidates, as then updates well which research capabilities. strong as we

creation leading has cell in vitro routing vector and Ultragenyx Solid’s screening Ultragenyx and company’s within of opportunities leveraging explore through our is optimize efforts light to I leveraged approach. the am microdystrophin novel our expression vivo an established to collaborating vectors the and development to Duchenne with containing leverage the expedited a In companies by the efforts, in therapies. HeLa producer and and share Ultragenyx The that constructs manufacturing next also this collaboration around research been line that internal have pleased productive generation with addition nNOS cell collaboration research optimization develop our to resources. that capsid assets. each been to of construction, other additional producer and has gene analytics have team candidate vectors line HeLa expertise we is very AAVX

program We on provide expect this XXXX. to an of update the by end

Earlier financials. As with microdystrophin ways having to filed that meaningful And patients expand Form these website. we to our to with ended it’s now to company And the detailed pipeline we Duchenne, in March patients’ contains turn XXXX which believe I will the to committed outcomes QX, XXXX, differences XX-Q XX, lives. for we multiple deliver for financial proprietary constructs today, our excited ability our on our are enhances make a quarter results. our opportunities. additional available Solid improving

ended going million commissions gross overallotment the cash in cash option do approximately highlight our financing balance discounts, Although we want closed expenses. This results public not full before proceeds quarter $XXX.X quarter detailed $XXX.X with exercise the to and offering, including resulting strengthened of in and today’s we further review of underwriting our call. during during offering million and the deducting equivalents. has sheet, the first I’m to XXXX, that I the of

that remarks. us to And expect and our of cash We enable our quarter now call expenses back cash Ilan find will for XXXX. the to fourth the I’ll equivalents closing into operating turn

Ilan Ganot

Thanks, Cathryn. Joel, Carl and

XXXX moment I priorities a take we milestones. Before questions, take your want to and anticipated to review our

community company is of friends. Duchenne want of out deeply therapies that horrible the SGT-XXX. first previously lives am. and additional a me, a second as X, increase making announced, and present every fun are as therapy, biopsy in and employees I’ll special for such for of for XXXX And year makes who quarter discussed were to our their remain long-term to obvious this is and As successfully and today their X is are Kids Joel on confidence expanding personal and biopsy see challenges they our that we for today. strategies just close Duchenne. milestones, recently from these improve go just this This we technologies, XX dosed. patients results to who address we as achieved one with to committed our reasons the advance gene and boys data in are Patients our encouraging have further with reality The today, to we day with for Duchenne by We commitment commitment the presented team our our one our Solid a pipeline day reiterating disease. in working track with every I what half

look you on make Duchenne mission. shared what and of preclinical employees, effective your day the updating clinical to therapy. what at and our is our our And questions. every the holds in and as also continued future to we challenges to We know is our community, progress the a us us different successes. dedication I for what now all This We’ll support to them through guides of take us Solid prospect continue our them giving without We inspires them build send for the programs. and future. drives commitment investors the forward

Operator

SVB Instructions] Your question of from the with line Leerink. comes first [Operator Joseph Schwartz

Joseph Schwartz

progress. first data, it’s encouraging to seems in which all like to opposed congrats is longer-term benefits and they delayed Everyone those the expression on on correspond most walk closely question or NSAA. My the it minute kinetics see SEC clinical correlate to six as

this points or take you with to or observation, across might of you NSAA just these about I thinking how end of as So therapy, clinical with chances are if a microdystrophin goal agree FDA. gene get advantage these SGT-XXX without establish a improve try the able three the was the that wondering, to composite such and to whether line being with or

Ilan Ganot

hear Great start on, question, to Carl think you will from Cathryn Joe. and will I Good finish.

Carl Morris

picked associations correlation, seems There Yes, as, an Yes. pretty good you you, three, that like. any sort make and quickly. can but you of out an that it’s of up to so be apparent

overall is biological muscles by the think different – at assays. I encouraged there different expected in took different time by data points. these We from variability,

So, over get and how see from expression It’s more that start at but we all that. based on to thinking, to clinical be sort really of it. specific relationships. turn increase to need happy not we trying data might the or are to sort to talk of we over about about it patients look sort Cathryn time. we I’ll of in would But an quite unexpected trial

Cathryn Clary

trial. measures about the encouraged in so certainly disease? which I most a these a to early patients Carl said, registration we’re our And designing in bit make really additional to correlation set How can lot How is long-term thinking what of it. way this outcome terms two And heart and – by functional patients analysis, that in We data far, robust we to use? that company, our find but a Sure. small so measure we benefit do do such and question as it’s heterogeneous we’re as we can which doing we about the for the although thinking Yes. look those on to encouraged a results. the we, asked we’re certainly Thanks a gets data you were We getting think by forward others question. of very start the decisions.

Joseph Schwartz

patients that as additional you not you SAE, was then appreciate what Okay, And the which And was tell for just you lab last look like and path in had or dosing, does complexity us about can from patient What as great. here? I wondering, can I say was triggered I with the that. SGT-XXX? future, heard characterize unexpected, the far this to be treated but you some clinical by could findings?

Ilan Ganot

Cathryn, you going. keep can

Cathryn Clary

Sure. yes. keep I’ll going just

So, it an patient our really The so the it as to some patient said, the other experts working perspective. way the of inflammatory not response it all fully why I external internally events was we understand less fix. was casualty looking from we’re patient unexpected, that which patients, similar elements We components safety. with had of in are ensure that a a both will is than still the severe severity of and move however with to at course, forward patient can

past patients. the dose about in asked You

we And and with working are need they to between minimum we’ll investigation. already in with our of a the case, XX of back dosing patient, of our be the to they will X next reviewed them built going We approve the X. course, Patients days DSMB, results and

then delay, was then we when bit Patient working of we’ll while FDA well. exactly dose a with a there going can’t be speculate X, to on as and we’re and already So,

Joseph Schwartz

Thank very you much.

Operator

comes question line from the with Barclays. And Wang your of Gena next

Gena Wang

my have for I questions. questions. you taking three Thank

the was to Patient X response. first The one inflammatory regarding

give you color additional this any wondering, regarding patient. Just can

You ASGCT, to safety did color at some related And think positive the showing the their understanding safety. activation. shared zero the I on Pfizer is present also, AAVX complement of of additional

you the was and question own collaboration, backbone internal derived more in patient this is zero a give in from SGT-XXX, question. the internal this prioritize? non-human on characteristics positive can have direction, look any Did is was this last and you [ph], future platelet question SLBXXX. count as kind information My My real other like baseline exactly What which more first with is response second what little primates can but give? That’s safety do for Do if a also for regarding non-human also, color an how that also, bit the SLBXXX. you inflammatory you – and the So, your the was you you primates? you patient see do test of what competition?

Ilan Ganot

Gena. questions, Awesome

and the I a hand going can talk start I’ll priorities Cathryn to that Carl it we’re about she the SLBXXX. to little bit and And think the finish off to SAE to talk with about talk over at then about then end.

Cathryn Clary

the for Gena you, question. Thank

seen evidence as, activation similar laboratory patients. eight we had did So had it actually of seen patients. asked the than that of some mentioned, compliment with X lab seen all not, Patient had an compliment of some interesting our activation. innate treated what response activation response, did the but in what lower inflammatory in before, compliment was activation we’ve we about aid as patient other some compliment elements It’s to an have in reported were in you and immune had is I part we patients of other

elements really it. factor somewhat investigation And We’re to that a provide the done, still we of see different and really examining patient once of the Patient appears we’re common our can results Every evaluating information. we certain with elements of be we haven’t some identified we still will, X. but additional are SAEs,

Carl Morris

is this And Carl. hi,

it’s if there the So, activate will ASGCT or the AAV can that’s place yes, share it antibodies of been presence both doesn’t system. complement has and we is AAVX AAVX, in and highlighting matter the

different an through, seen, So, this be is we will programs. think within effect that

well. handle think we’re And better it. as companies other a seeing that I on are So, getting

we that SLBXXX Regarding the is and SGT-XXX rational capsid did some internally. from design derived

from identified number at a to, and how of looked expertise of think rather using other went It’s in on So And right our number through analysis, plan. than we sort the target muscles And optimization early computational to about specifically. companies best we lead I the like that muscle of capsids of way a look very in going sort a now. promising. we’re still

the Once there’s finalized we sort possible. to specific So, soon and identified, as of haven’t transgene using. as it we’ve but as we candidate, well we’re a moving IND-enabling that be capsid into specific planted studies that

to I’ll pass back So, it Ilan.

Ilan Ganot

Just to that good complimentary manufacturing actually skillsets we’re say about Ultragenyx, that, it There’s system DMD, here two and making real to – seeing the but I therapy with be the too. some collaborate. during another progress teams people enjoyed there’s happens here, their when you in think gene with Cambridge are

those update therapy. in future. and like therapies potential on [ph], There’s in And And other to disorders, programs patients just numbers. would both additional to So, gene we that confusing for And, can lot keeps from call programs you’ve is could and we SGT-XXX the DMD before, they there a people of next me be heard good be committed to many as there, I good are forward that look just I probably gene very I but so chemistry think the next I and generation leading the think SLBX, they needs. in continuing programs. steps with way advance me really any Gena the involved are helping ever this don’t on a musculoskeletal massive think unmet I communication to there’s well companies. consider say as say there existing more such a

Gena Wang

much. very you Thank

Ilan Ganot

Gena. you, Thank

Operator

Goldman question And from the of Richter comes your line Sachs. with Salveen next

Unidentified Analyst

Hi, Sonia question. is so taking much for thanks This Salveen. on for our

second happen that are initial happened? why And currently I the on evaluating additional any going we you. was X? in any caused data X have what when and functional just So, Patient you’re Do Patients know might’ve to information Thank our hypothesis then see you from X? to question

Ilan Ganot

Sonia. Hey, thank Cathryn? you,

Cathryn Clary

the So thanks question. for very much

really, speculate at causality to several don’t now on right are because we things. I looking So want we

patients of safe our deem And a have saw we had to similar new our that other Patient be X severe investigator event than and dosed does are As elements some under we reported, dosing. to it that very protocol drug principal less in our X did the Patient course related.

before, a some evaluating factors. definitely So, said have get when you we we’re number what the handle on better I as we’ll happened of and causes back were. And what a to of exactly different

don’t XX of because terms day steroids is still We at a really the the look days XX at in Patient the functional functional data, In ingrained or data reported It’ll of X a visit. be while. approaching system.

be be while functional haven’t there’ll And So, a we additional data. there’ll to before that. guided actually

Operator

next [Operator Gbola Chardan. question Amusa the line from of Instructions] Your with comes

Gbola Amusa

for taking Thanks my call. Hi.

data questions a assays, Just three noteworthy couple equals – X cetera, about an it’s know Patients to X, wanted long-term et I there’s in cetera. the on it’s And to et pretty stuff. variability

there what And easy then it’s you a Patient that could X Patients X? versus make forward to and you Patient in a and conclusions. for And results going again, we can’t anything be know can on X are factors X. X Patient more do is dosing could like that I in play early So, that create days. might encourage update you see But difference us any hypothesis you have on what

Ilan Ganot

know, days two asked Hey, ago. have I Carl’s This to to him because I is good that you. Gbola, question. it’s him

Carl Morris

of We Yes. got just these these started analyzing just – we pulled data very recently. sort and in

stabilize finding if sort seeing It’s membrane it is the in our type a sort that results more look improved and the unexpected, good about generating good and not we just – these from all time [indiscernible] they’re it’s guess, assays, does of but a on of of spaces very sort very given think set responses do and encouraging. have So to of I we’re This – dose fill a it is overtime. of dose you then we’re continued overall in early, and assays confidence muscle. production different

very a of levels encouraging. had very trials, lot was quantitation, not level – Patient at this. thinking unfortunately, like non-responders We’ve it’s time and lower levels. responders, still below X all look with mechanisms Patient detectable and to the to unfortunately X started So as obviously spend got about drug you have of

just there here So threshold Patient importantly, that aware of. that are back see we trend be did some in But we effect functional X March. in improvements may a not presented

even there’s coming really sort The we’re results looking less of definitely think is to something I be So, going promising overall that than with out. of X%, increase into. set

Ilan Ganot

because Gbola I’ll because this durability, add, all that here, notion have it ended being couldn’t long-term delayed just year were clinics year would year up we one being to data. patients two a of closed, – the lucky COVID. biopsy was that up up got ends one of just little add because year now visit we a and And be show supposed later, I

I therapies, all gene notion improved do that time, clearly think hard continued the disappears so is you disease of to a when I’d the duration, measure feature. hope months. like or in to of even this three is the Duchenne, the a notion us that of And going are confidence after you lot to that is that going such outcomes. think biomarkers functional obviously like to six just provide not about something with durability or

Gbola Amusa

it. quickly. just Got really one another And

maybe But to can that what’s watch is there cetera. forward? art there for the et referred isn’t of in I I that seen AAV equals we like reason know et on an or I this to feel it’s be to delay and magnitude cetera, might and in of biological Solid the think seems phone going why earlier space. kinetics sort kinetics, elsewhere But real apples the state had delayed greater of phenomenon here three, a change call oranges know explanation the and reasons we

Ilan Ganot

of becomes slow the Gbola, you I’d get grow protein in healthier build. positive production And in being about therefore, that’s – and SGT-XXX be talk this. every while it’s occurring. love stabilization sort may pre-clinical it more the time there, we protein. nuclei about But muscle kinetically, that – of XX positive consistent of a as we our for instead myonuclei a in produce muscle more there speculation production continued if more with can days More sort a to of there. Again, models see very increases. There’s healthy, stable, fused all generally after could to

Patient doubling apparent doubling in a see Patient X an a threefold parent. and do we in X, a So, patients, again,

someone there other a years was we things importantly, about not have but be factor, fall And We age, age could of age. So, and that fall patient’s know about XX really a actually happening. be older. asked patient was don’t could

be So we forward. to really need that’s as move thinking we that about something

Operator

your question the from next with comes Mirchandaney of Maneka line And Evercore.

Maneka Mirchandaney

the Great. that Thanks drugs the inflammatory Based any like there in on other like? timing that these you’re further are what factors, and able dose the of or or to might think potential X, changes you question. Patient the for protocol events, seeing taking in decrease risk what do for look immunosuppressive changes might be of the additional Thanks.

Joel Schneider

so obviously, same. pretty first, want are thing solution And from And if idea hopefully to will a identify I take that But things out, patient. mean, at that, I to got if serious great a I other need to every just that’s I’ll be And is hopefully some. the end to a learned happy at that doing the again, she’s much tweaked companies Cathryn long-term a alive we have feel and and very Cathryn make it. here problem. the place

Cathryn Clary

external the modify we including consulting we’re I we are Maneka. right risk understand I questions experts they’re the profile consultants really in our it’s mitigation an of a with the safety will think is one that are these investigation, way biggest with the potentially some – events such of can obviously, Sure, important really, and the mean, mean, in that probably middle And thanks, we And still now really safety. optimize area. question. patients that grappling first who with concern to is so this in

is that still exploring So, and we’re certainly changes, need hypothesis approved will we I our really what we to our by different really we to options. can’t this FDA DSMB really course, well. at do But because have don’t with those protocol decide share shared and of point, will you make be as If tell with – you. and when

and doses also of dosing, question I one the things we’re is is that is but that at, the potentially, looking asked options. other you think the about,

Operator

you. Thank

line the JPMorgan. with question Your Anupam next of from Rama comes

Anupam Rama

for Thanks question. much Hi guys. so the taking

from clarification being FDA are timelines a SAE feedback what the of profile has for of the groups? and this and DSMB, sort both Just here, shared patient of and question those patient the with clinical

Ilan Ganot

and the FDA ongoing Anupam. we Absolutely, have with DSMB with we shared Hi, the and dialogues.

and timelines, We but been really have are discussed. able to shared not project

Anupam Rama

so Thanks much it. questions. our for taking Got

Operator

any there further And Are are at this there questions. time, no audio closing remarks?

Ilan Ganot

thanks And dialing have mean, great I a for in. Thank everybody forward to look, talking weekend. look we And again you. soon.

Operator

today’s your Thank participation. concludes call. for conference you This Thank you.

now may You disconnect.

Solid Biosciences (SLDB) 14 May 212021 Q1 Earnings call transcript